Last reviewed · How we verify
Meningococcal ACWY
Meningococcal ACWY is a Biologic drug developed by Canadian Immunization Research Network. It is currently FDA-approved.
At a glance
| Generic name | Meningococcal ACWY |
|---|---|
| Sponsor | Canadian Immunization Research Network |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-Term PF-06651600 for the Treatment of Alopecia Areata (PHASE3)
- Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents (PHASE1, PHASE2)
- Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction (PHASE4)
- Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine (PHASE3)
- Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults (PHASE3)
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (PHASE3)
- Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia (PHASE3)
- MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Meningococcal ACWY CI brief — competitive landscape report
- Meningococcal ACWY updates RSS · CI watch RSS
- Canadian Immunization Research Network portfolio CI
Frequently asked questions about Meningococcal ACWY
What is Meningococcal ACWY?
Meningococcal ACWY is a Biologic drug developed by Canadian Immunization Research Network.
Who makes Meningococcal ACWY?
Meningococcal ACWY is developed and marketed by Canadian Immunization Research Network (see full Canadian Immunization Research Network pipeline at /company/canadian-immunization-research-network).
What development phase is Meningococcal ACWY in?
Meningococcal ACWY is FDA-approved (marketed).
Related
- Manufacturer: Canadian Immunization Research Network — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing